$MCRB

Seres Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$3.19 -

Extented Hours

VOLUME

854,637

DAY RANGE

2.97 - 3.22

52 WEEK

2.91 - 25.06

Join Discuss about MCRB with like-minded investors

profile
@Pyrognosis #droscrew
recently

ARK Funds sells: Seres Therapeutics (MCRB) - 31,256 DocuSign (DOCU) - 36,909 Shopify (SHOP) - 12,822 Square (SQ) - 68,017 Trimble (TRMB) - 18,810 Cellectis (CLLS) - 4,834

115 Replies 14 👍 9 🔥

profile
@CarlosH-carvan #ivtrades
recently

Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Aug. 12, 2021: OPEN, VEEV, SEER, RHHBY, REGN, PSTI, NVS, NTDOY, TWTR, DOCU, TER, SQ, SHOP, IOVA, SE, MCRB, XONE, GOOG, DDD, BYDDY, TTD, BABA BZ Wire Opendoor Technologies (OPEN) - 523,533 Shares Veeva Systems (VEEV) - 26,068 Seer (SEER) - 14,750 Roche (RHHBY) - 132,596 Regeneron Pharmaceuticals (REGN) - 42,669 Pluristem Therapeutics (PSTI) - 92,900 Novartis (NVS) - 92,693 Nintendo (NTDOY) - 114,850 Twitter (TWTR) - 252,465 DocuSign (DOCU) - 50,178 Teradyne (TER) - 90,909 Square (SQ) - 128,880 Shopify (SHOP) - 22,209 Iovance Biotherapeutics (IOVA) - 81,694 Sea (SE) - 109,453 Seres Therapeutics (MCRB) - 269,026 ExOne (XONE) - 167,773 Alphabet (GOOG) - 2,066 3D Systems (DDD) - 79,917 BYD (BYDDY) - 10,725 The Trade Desk (TTD) - 176,259 Alibaba (BABA) - 8,062

108 Replies 12 👍 15 🔥

profile
@dros #droscrew
recently

Upgrades 7/23: $AAL $BANC $CBT $DHI $ERF $LIND $MMC $MNST $PLAN $SBUX $TPH $TTD $TX $UAL $VNE $VERI $WRLD $WSO  . Downgrades 7/23: $ADVM $DPZ $FTI $LPRO $MCRB $SAM $SQM

60 Replies 14 👍 6 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

except MCRB was phase 3

108 Replies 15 👍 10 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

reminds me of $MCRB

132 Replies 15 👍 12 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

Ever since my blow up on $MCRB last month, I really took the time to learn more about myself and my trading, to identify my mistakes and fix them. Today I paper traded $SUNW like how I would trade it on my account, and was really happy with the results. Was 1500 shares max. 6/6😋

133 Replies 8 👍 11 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

similar with $MCRB and $EQ

82 Replies 8 👍 12 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

giving me $MCRB vibes...

132 Replies 7 👍 15 🔥

profile
@Neptune5045 #StockTraders.NET
recently

$MCRB covered too early ughh LOL

137 Replies 9 👍 14 🔥

profile
@Neptune5045 #StockTraders.NET
recently

nice $MCRB covered 24.7s from ystd

53 Replies 8 👍 7 🔥

profile
@Neptune5045 #StockTraders.NET
recently

looking to close $MCRB at 25s tmr

50 Replies 12 👍 7 🔥

profile
@Neptune5045 #StockTraders.NET
recently

$MCRB beautiful

108 Replies 8 👍 7 🔥

JR
@jrutkows645 #StockTraders.NET
recently

My PM analysis on MCRB.

111 Replies 15 👍 10 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

$MCRB was a $4 penny stock, but I just skimmed through the news and didn’t realize that it was a phase 3 endpoint success and that it was a prior $20 stock

41 Replies 14 👍 7 🔥

profile
@Neptune5045 #StockTraders.NET
recently

what about MCRB lol > @FillTheGapToZero said: but sometimes, you gotta filter out fluff from actual news, like with MCRB

44 Replies 10 👍 6 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

but sometimes, you gotta filter out fluff from actual news, like with MCRB

42 Replies 9 👍 9 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

blew up on WIMI and MCRB...

90 Replies 7 👍 13 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: low hanging fruits $NTN, $IGC, $FAT....possible fades: $PEIX, $MCRB

64 Replies 9 👍 13 🔥

profile
@Neptune5045 #StockTraders.NET
recently

$MCRB crazy

99 Replies 8 👍 14 🔥

ES
@Esdrasack #StockTraders.NET
recently

$MCRB I dont like trade this choppy level But I got cheap puts just in case it goes to 15 - 12 on next days

131 Replies 7 👍 12 🔥

profile
@TraderXx #StockTraders.NET
recently

$MCRB is strong as hell, gotta be careful with this one, would not be surprised to se it it well above HOD

104 Replies 11 👍 7 🔥

profile
@TraderXx #StockTraders.NET
recently

Cov $MCRB @ 26.79

90 Replies 9 👍 15 🔥

profile
@TraderXx #StockTraders.NET
recently

ss $MCRB at 31.53

130 Replies 13 👍 11 🔥

JR
@jrutkows645 #StockTraders.NET
recently

$MCRB said to myself after fundy research: "If this traps shorts at open it's probably a long." >Proceeds to stare at screen once that exact thing happens.

116 Replies 6 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$MCRB nasty

122 Replies 12 👍 15 🔥

profile
@CarlosH-carvan #ivtrades
recently

$MCRB halted

150 Replies 13 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

yup, i'm just avoiding $MCRB havent touched it

111 Replies 13 👍 14 🔥

JR
@jrutkows645 #StockTraders.NET
recently

$MCRB doing institutional f*ckboy stuff. Would not be surprised if it grinded higher. Can't trust any crack.

136 Replies 14 👍 8 🔥

profile
@CarlosH-carvan #ivtrades
recently

6800 MCRB Oct20 10.0 Calls $9.70

104 Replies 11 👍 14 🔥

I2
@I2L #droscrew
recently

will do dros...I was looking at MCRB seems wild

60 Replies 13 👍 9 🔥

profile
@Roscoe #LWT Trading
recently

$MCRB $KODK $IBIO watches

148 Replies 7 👍 10 🔥

Key Metrics

Market Cap

276.69 M

Beta

1.20

Avg. Volume

883.41 K

Shares Outstanding

92.23 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-02

Next Dividend Date

Company Information

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.

CEO: Eric Shaff

Website:

HQ: 200 Sidney St Cambridge, 02139-4218 Massachusetts

Related News